Vericel Corp Ord (VCEL) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.

Total Revenue Chart for Vericel Corp Ord

Vericel Corp Ord (VCEL) revenue for FY2025 was USD 276.3M, a 16.5% change from FY2024. Vericel Corp Ord's revenue grew from USD 1.6M in 1995 to USD 276.3M in 2025 (17166.2% over 30 years). Earnings per share moved from USD -10.19 in 2011 to USD -0.35 in 2022. Revenue compound annual growth rate: 5-year CAGR of 17.3%, 10-year CAGR of 18.4%, 20-year CAGR of 33.1%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$2.18B
Implied Share Price
$42.53
Enterprise Value
$2.28B
Revenue (TTM)
$306.30M
EBITDA
$31.15M
Profit Margin
7.91%
Trailing P/E
90.49
Forward P/E
97.09
Price/Book (MRQ)
6.36
Price/Sales (TTM)
7.11
EV/EBITDA
59.10
EV/Revenue
7.46
Dividend Yield
—
Book Value
$7.23
Free Cash Flow (FY2025)
$24.75M
Free Cash Flow Yield
1.14%

Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.